⌘K
Loading ticker…
AnaptysBio, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, AnaptysBio, Inc. Common Stock (ANAB) has a 3-month relative strength percentile of 35 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 73. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.3%, relative volume 2.51×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
35 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ANAB is in a stage 2 uptrend, week 1. Currently in a 51-day base; basing ADR 6.5% (broad 6.5%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 6.1% / 29.7%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
ANAB is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $34M notional. Top 3 carry $87M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $34M |
| XBIState Street SPDR S&P Biotech ETF | 0.38% | $28M |
| IWMiShares Russell 2000 ETF | 0.03% | $25M |
| VXFVanguard Extended Market ETF | 0.01% | $12M |
| IWOiShares Russell 2000 Growth ETF | 0.07% | $8M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $1M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ANAB Jan avg: 5.93% median: 3.98% win: 50% σ: 23.17% n: 4 2022-04-12 → 2026-05-29 | ANAB Feb avg: 4.54% median: 4.11% win: 75% σ: 9.71% n: 4 2022-04-12 → 2026-05-29 | ANAB Mar avg: -3.28% median: -5.52% win: 50% σ: 11.05% n: 4 2022-04-12 → 2026-05-29 | ANAB Apr avg: 7.01% median: 8.08% win: 60% σ: 12.32% n: 5 2022-04-12 → 2026-05-29 | ANAB May avg: -8.80% median: -8.26% win: 20% σ: 8.26% n: 5 2022-04-12 → 2026-05-29 | ANAB Jun avg: 4.48% median: 5.58% win: 75% σ: 3.23% n: 4 2022-04-12 → 2026-05-29 (current) | ANAB Jul avg: 12.42% median: 6.87% win: 75% σ: 18.60% n: 4 2022-04-12 → 2026-05-29 | ANAB Aug avg: 0.72% median: 4.59% win: 50% σ: 12.90% n: 4 2022-04-12 → 2026-05-29 | ANAB Sep avg: 9.92% median: 0.56% win: 50% σ: 28.79% n: 4 2022-04-12 → 2026-05-29 | ANAB Oct avg: -3.02% median: 1.95% win: 50% σ: 24.86% n: 4 2022-04-12 → 2026-05-29 | ANAB Nov avg: 2.93% median: 4.82% win: 50% σ: 14.02% n: 4 2022-04-12 → 2026-05-29 | ANAB Dec avg: 8.27% median: 14.28% win: 75% σ: 40.82% n: 4 2022-04-12 → 2026-05-29 |